Prescribing information



Watch the video from the 2021 PCCS Conference: ‘Addressing health inequalities in Heart Failure: a real world case study’.

Indication: Entresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.1

HFrEF, heart failure with reduced ejection fraction.



  1. Entresto Summary of Product Characteristics, 2021. 
Rate this content: 
No votes yet
UK | December 2021 | 165125

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]